Blue Crest Capital Management LTD Esperion Therapeutics, Inc. Transaction History

Blue Crest Capital Management LTD

  • $1.62 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$1.46 - $7.3 $37,121 - $185,609
25,426 New
25,426 $40,000
Q4 2018

Feb 14, 2019
SELL
$36.99 - $59.11 $256,784 - $410,341
-6,942 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$40.74 - $51.41 $282,817 - $356,888
6,942 New
6,942 $308,000
Q4 2017

Feb 14, 2018
SELL
$43.47 - $67.43 $221,653 - $343,825
-5,099 Closed
0 $0
Q3 2017

Nov 14, 2017
BUY
$43.8 - $52.77 $223,336 - $269,074
5,099
5,099 $256,000

Others Institutions Holding ESPR

# of Institutions
211
Shares Held
129M
Call Options Held
1.67M
Put Options Held
930K
View Full List

About Esperion Therapeutics, Inc.

ESPR Quotes by TradingView
  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $124M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Blue Crest Capital Management LTD Portfolio

Follow Blue Crest Capital Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Blue Crest Capital Management LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email